Psychedelic medicine pioneer exits MDMA biotech after regulatory blow

Doblin leaves Lykos Therapeutics board after work on treatment for PTSD suffered setback from FDA ruling

from News Feed https://ift.tt/ZLNdsTp
via IFTTT